Maret L Maliniak1, Arlene A Stecenko2, Nael A McCarty3. 1. Department of Pediatrics, Emory University, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Emory+Children's Center for CF and Airways Disease Research, 2015 Uppergate Drive, Atlanta, GA 30322, USA. Electronic address: maret.maliniak@gmail.com. 2. Department of Pediatrics, Emory University, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Emory+Children's Center for CF and Airways Disease Research, 2015 Uppergate Drive, Atlanta, GA 30322, USA. Electronic address: astecen@emory.edu. 3. Department of Pediatrics, Emory University, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA 30322, USA; Emory+Children's Center for CF and Airways Disease Research, 2015 Uppergate Drive, Atlanta, GA 30322, USA. Electronic address: namccar@emory.edu.
Abstract
BACKGROUND: Few studies have examined the association between chronic methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PA) co-infection and health outcomes despite evidence that these pathogens alone contribute to higher morbidity and mortality in cystic fibrosis (CF). This study examines outcomes among CF patients with chronic MRSA and PA co-infection compared with patients with either or neither of these organisms. METHODS: CF patients attending the care center in Atlanta, GA from 2007-2013 comprised the study cohort. Chronic co-infection was defined as >50% PA+ cultures and >50% MRSA+ cultures and modeled as time-varying. The rate of decline in lung function (FEV1) and the rate of IV treatments were the main outcomes. RESULTS: Among all patients (N=354), chronic co-infection was associated with a significantly more rapid rate of FEV1 decline compared with patients with chronic PA alone [adjusted difference: -0.60% predicted/year (-1.13, -0.08)] and chronic MRSA alone [adjusted difference: -0.89% predicted/year (-1.56, -0.22)]. Rate of IV treatments was significantly higher among patients with chronic co-infection compared with patients with chronic PA alone [adjusted IRR: 1.24 (1.01, 1.52)] and chronic MRSA alone [adjusted IRR: 1.34 (1.03, 1.74)]. CONCLUSIONS: Data from the Atlanta Care Center suggest that chronic MRSA and PA co-infection may be associated with increased rate of lung function decline and rate of intravenous antibiotics compared with patients with either pathogen alone.
BACKGROUND: Few studies have examined the association between chronic methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PA) co-infection and health outcomes despite evidence that these pathogens alone contribute to higher morbidity and mortality in cystic fibrosis (CF). This study examines outcomes among CF patients with chronic MRSA and PA co-infection compared with patients with either or neither of these organisms. METHODS: CF patients attending the care center in Atlanta, GA from 2007-2013 comprised the study cohort. Chronic co-infection was defined as >50% PA+ cultures and >50% MRSA+ cultures and modeled as time-varying. The rate of decline in lung function (FEV1) and the rate of IV treatments were the main outcomes. RESULTS: Among all patients (N=354), chronic co-infection was associated with a significantly more rapid rate of FEV1 decline compared with patients with chronic PA alone [adjusted difference: -0.60% predicted/year (-1.13, -0.08)] and chronic MRSA alone [adjusted difference: -0.89% predicted/year (-1.56, -0.22)]. Rate of IV treatments was significantly higher among patients with chronic co-infection compared with patients with chronic PA alone [adjusted IRR: 1.24 (1.01, 1.52)] and chronic MRSA alone [adjusted IRR: 1.34 (1.03, 1.74)]. CONCLUSIONS: Data from the Atlanta Care Center suggest that chronic MRSA and PA co-infection may be associated with increased rate of lung function decline and rate of intravenous antibiotics compared with patients with either pathogen alone.
Authors: James M Kidd; Colleen M Sakon; Louise-Marie Oleksiuk; Jeffrey J Cies; Rebecca S Pettit; David P Nicolau; Joseph L Kuti Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Suzanne M J Fleiszig; Abby R Kroken; Vincent Nieto; Melinda R Grosser; Stephanie J Wan; Matteo M E Metruccio; David J Evans Journal: Prog Retin Eye Res Date: 2019-11-20 Impact factor: 21.198
Authors: Anthony J Fischer; Sachinkumar B Singh; Mason M LaMarche; Lucas J Maakestad; Zoe E Kienenberger; Tahuanty A Peña; David A Stoltz; Dominique H Limoli Journal: Am J Respir Crit Care Med Date: 2021-02-01 Impact factor: 21.405